Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13335547 | 0.81 | HRH3 (0.64) | HRH3KCNH2HTR3A | |
| SCHEMBL30786184 | 0.80 | LTA4H (0.52) | HTR3A | |
| SCHEMBL74064 | 0.78 | HRH3 (0.57) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL74140 | 0.75 | HRH3 (0.59) | HRH3KCNH2HRH1HRH4 | |
| SCHEMBL75427 | 0.74 | HRH3 (0.61) | HRH3KCNH2HRH1HRH4 | |
| SCHEMBL74060 | 0.74 | HRH3 (0.52) | HRH3KCNH2HRH1HRH4 | |
| SCHEMBL492205 | 0.73 | HRH3 (0.84) | HRH3KCNH2HRH1HRH4DRD2 | |
| SCHEMBL1880973 | 0.73 | HRH3 (0.61) | HRH3KCNH2HRH1HRH4 | |
| SCHEMBL3581930 | 0.73 | HRH3 (0.89) | HRH3KCNH2HRH1 | |
| SCHEMBL1879652 | 0.73 | HRH3 (0.55) | HRH3KCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | claimed |
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | GPR119, HCRTR2, HCRTR1 | HRH3 986/4885KCNH2 2244/4885HRH1 1390/4885 |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1299/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.